GeoVax Labs Inc News - GOVX

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax...

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19...

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc...

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...

GeoVax to Participate in Upcoming Investor Conferences in September

ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Registration is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO

Company to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for...

GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market

ATLANTA, GA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

silkman 2 weeks ago

Bullish?

👍️0

glenn1919 2 weeks ago

GOVX....................................https://stockcharts.com/h-sc/ui?s=GOVX&p=W&b=5&g=0&id=p86431144783

👍️0

Snoop_dog 3 weeks ago

Anyone know if they working on H5N1?

👍️0

PonkenPlonken 3 weeks ago

go go

👍️0

glenn1919 3 weeks ago

GOVX...................................https://stockcharts.com/h-sc/ui?s=GOVX&p=W&b=5&g=0&id=p86431144783

👍️0

tw0122 3 weeks ago

GOVX $3.57 + 80% kept a few $1.70s.

👍️0

tw0122 3 weeks ago

GOVX $2.80s + 50%🔥🔥🔥🔥📞🚀🚀🚀🚀

👍 1 🚀 1

tw0122 3 weeks ago

Rockets fired $2.70s + 40% sold most

👍 1 🚀 1

glenn1919 3 weeks ago

govx...............................https://stockcharts.com/h-sc/ui?s=GOVX&p=W&b=5&g=0&id=p86431144783

👍 1 🚀 1

tw0122 3 weeks ago

GOVX $1:96 + 1% earnings 11-12

👍️0

tw0122 3 weeks ago

Have plenty of $1.70s financial results Nov 12 afterhours

👍️0

tw0122 1 month ago

Some climbing again 2.26

👍️0

PonkenPlonken 1 month ago

crawling out of its hole
keep on watch

👍️0

tw0122 1 month ago

GOVX 2.20s offshore hedgies hit some.. The government will also provide around $343M for a clinical research organization to conduct the clinical trial. Under the agreement, BARDA will award GeoVax up to $45M for the manufacturing of clinical materials and support for the Phase 2b study

👍️0

Trompete 2 months ago

GARBAGE, TRASH, WORTHLESS

👍️0

tw0122 2 months ago

$2.07 Offshore hedgies could hit here again but could be a month or two out still

👍️0

tw0122 2 months ago

Ok $1.90- $2s flipper

👍️0

tw0122 2 months ago

Confirm reversal on candle on 3rd day

👍️0

tw0122 2 months ago

Ok ok we see you ..but going to hold $3s this time or another fake out. Support been at $2.60s past few weeks. Looking better

👍️0

tw0122 3 months ago

Mpox has spread to at least 14 African countries, including Morocco, which has confirmed its first case in the current outbreak. (Source: BBC Africa)
The Democratic Republic of Congo (DRC) is the epicenter of the outbreak, with over 20,000 cases reported and more than 500 deaths. (Source: WHO)
Neighboring countries, such as Burundi, Kenya, Rwanda, and Uganda, have also reported cases. (Source: WHO)
Vaccination Efforts

The World Health Organization (WHO) recommends use of MVA-BN or LC16 vaccines, or the ACAM2000 vaccine when others are not available. (Source: WHO)
Only people at risk of exposure to mpox should be considered for vaccination, according to WHO. (Source: WHO)
Transmission and Prevention

Mpox is primarily spread through close person-to-person contact with someone who is infected, including through sex. (Source: Nature)
Cleaning and disinfecting surfaces or objects and washing hands after touching contaminated surfaces or objects can help prevent transmission. (Source: WHO)
Avoiding unprotected contact with wild animals, especially those that are sick or dead, and cooking food thoroughly can reduce the risk of getting mpox from animals. (Source: WHO)
Public Health Emergency

The WHO declared the mpox outbreak a Public Health Emergency of International Concern (PHEIC) on August 19, 2024, citing the rapid spread of a new, more transmissible strain of the virus. (Source: WHO)
Research and Development

Scientists are racing to answer questions about the outbreak, including whether vaccines will curb the spread and how the virus is transmitted. (Source: Nature)

👍️ 1

tw0122 3 months ago

Looking good bottom about in for hedgies

👍️0

tw0122 3 months ago

Watch for 2.52 - .2.92 too hold for flip. 2.08- 2.20 next zone underneath if doesn’t

👍️0

tw0122 3 months ago

Hedgies determine new downtrend. New entry as we see $2.80s for another flip

👍️0

tw0122 3 months ago

Ok hedgies confirming new upward trend perhaps give it a few hours still

👍️0

tw0122 3 months ago

Flip the $3.06 at 3.30s and wait for hedgies to determine direction

👍️0

tw0122 3 months ago

Tummies yummy $3.06 bought and then if happens to test next level down add again.
Hedgies want to take it as low as possible before the next big run into Covid vaccine season. Luv you Gary Gensler

👍️0

tw0122 3 months ago

Good sign 3.06 hedgies covering shorts now volume picking up 600,000. Almost time to add some more goodies

👍️0

tw0122 3 months ago

3.19 zone being tested if holds a few days start adding some again

👍️0

tw0122 3 months ago

price of $5.125 per share for expected gross proceeds of $5 million.

4:39 AM EDT, 08/29/2024 (MT Newswires) -- GeoVax Labs (GOVX) said late Wednesday it has agreed to sell 975,610 common shares in a registered direct offering to an institutional investor at a price of $5.125 per share for expected gross proceeds of $5 million.

The company will also issue warrants to purchase up to 975,610 common shares to the investor in a concurrent private placement, it said. The warrants will be exercisable at a price of $5 per share.

Net proceeds will be used for working capital and general corporate purposes, the company said.

The offering is expected to close around Friday, sub

👍️0

tw0122 3 months ago

Test 3.19- 3.55 zone wait to confirm before pulling trigger $2.52- 2.92 is the other zone. The hedgies that have most of the shares will determine that as they move this one as they please

👍️0

tw0122 3 months ago

Covid flue season blooming still holding a few here but inclined to add some more ..

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

👍️0

Gman3343 3 months ago

Going under 2.00 then time to buy.

👍️0

Monksdream 3 months ago

GOVX under $5

👍️0

81vette 3 months ago

Warrents jumped up 100%

👍️0

Biggiee 3 months ago

The Fauch knows how to party!

👍️0

Gman3343 3 months ago

Maybe the evil bastard will drop dead .

👍️0

tw0122 3 months ago

Buy 6.30s sell $7.30s was todays lesson dip time coming again.. Dr. Fauci Somehow Contracts Ultra-Rare West Nile Virus On Heels Of COVID-19 Infection

👍️0

Gman3343 3 months ago

Good, keep giving that evil idiot all my vaccines and boosters.
He should double up

👍️0

tw0122 3 months ago

Catch the dips play next.. Dr. Fauci has COVID again for the third time and has been vaccinated and boosted six times

👍️0

glenn1919 3 months ago

GOVX...............................https://stockcharts.com/h-sc/ui?s=GOVX&p=W&b=5&g=0&id=p86431144783

👍️0

tw0122 3 months ago

sale of 1,700,000 shares of the Company’s common stock (or common stock equivalents) at a price of $5.00 per share in a registered direct offering priced above-the-market under Nasdaq rules.
In addition, in a concurrent private placement, the Company will issue to the investor warrants to purchase up to 1,700,000 shares of common stock. The warrants have an exercise price of $5.00 per share, will be exercisable immediately following the date of issuance and will have a term of five years from the date of issuance.

👍️0

ipo_dude 3 months ago

I wish ..

👍️0

rouge Vaughn 3 months ago

15 to 20 let's goooo

👍️0

tw0122 3 months ago

Next stop $15 then $20…By Amanda Alvarado
Published: Aug. 21, 2024 at 8:02 AM EDT
(Gray News) - COVID-19 cases are rising and KP.3.1.1 is the predominant variant in the United States, according to the Centers for Disease Control and Prevention.

The variant accounted for between 31% and 43% of the cases in the two-week period ending on Aug. 17.

KP.3.1.1 is currently the only major variant increasing in proportion nationally, according to the CDC.

Emergency room visits diagnosed as COVID-19 started increasing in May in the West and are now the highest in the South and Southeast. The wastewater viral activity level for COVID-19 has been rising since mid-May and is currently very high across most parts of the country, according to the CDC.

👍️0

tw0122 3 months ago

- Kamala Harris issues vaccine mandate for campaign workers..Good news for vaccine makers pump em up.

👍️0

tw0122 3 months ago

Still have $1.80 shares left from a couple weeks back holding for the Gold longer term rest been cashed out

👍️ 1

glenn1919 3 months ago

GOVX....................................https://stockcharts.com/h-sc/ui?s=GOVX&p=W&b=5&g=0&id=p86431144783

👍️0

Backstabbed 4 months ago

Damn… nice play guys. Missed this one. I bought my first stock today in months!

Been terrible year

👍️0

81vette 4 months ago

Huge winner today,warrents was even better because of big spread, easy 15-19% wins

👍️0

gail 4 months ago

and back out before the dump, but it tried.

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

GeoVax Labs Inc (GOVX)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

GOVX News

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GeoVax to Participate in Upcoming Investor Conferences in September

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Registration is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO

GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

GOVX Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

GeoVax Labs Inc (GOVX) News

GeoVax Labs Inc (GOVX)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

GOVX News

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GeoVax to Participate in Upcoming Investor Conferences in September

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Registration is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO

GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

GOVX Discussion

Your Recent History

Company

Business

Popular

Get The App